Point-of-care testing is the fastest-growing channel in IVD by site of testing, driven by the permanent behavioral shift toward decentralized diagnostics accelerated by COVID-19. The POC testing market is projected to grow at a CAGR exceeding 8% through 2030, outpacing central laboratory growth. Abbott's BinaxNOW and ID NOW platforms demonstrated the commercial power of near-patient diagnostics at scale. Pregnancy, influenza, strep, glucose, and COVID antigen tests have normalized home testing for hundreds of millions of consumers globally. Decentralized testing through at-home IVD kits is emerging as a transformative trend empowering individuals to monitor health conditions conveniently and privately. Emergency departments are deploying point-of-care troponin, BNP, and blood gas analyzers to accelerate clinical decisions. Microfluidics, biosensors, and smartphone-connected diagnostics are enabling test-menu expansion into previously laboratory-only applications.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• POC Testing Market Size and Forecast 2025-2030 by Application and Channel
• Emergency and Critical Care POC — Troponin, BNP, Blood Gas, and Electrolytes
• Infectious Disease POC — Influenza, Strep, RSV, COVID, and Syndromic Panels
• Chronic Disease POC — Glucose, HbA1c, Lipids, and INR
• At-Home Testing — OTC Diagnostics, Direct-to-Consumer, and Prescription Home Test Markets
• POC Molecular Testing — GeneXpert, ID NOW, and Near-Patient NGS
• Microfluidics and Biosensor Technologies — Enabling the Next POC Generation
• Regulatory Framework — FDA, CLIA Waiver, and EU IVDR for POC Devices
• Competitive Landscape — Abbott, Roche, Siemens, QuidelOrtho, and Emerging Players
• Investment and Partnership Opportunities
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Highest-priority POC opportunities
- Competitive landscape summary
- Strategic recommendations
2. Market Overview
- Market definition, scope and segmentation
- Key demand drivers and restraints
- Regulatory environment — FDA CLIA Waiver, OTC clearance, and EU IVDR self-test
3. Emergency and Critical Care POC
- Troponin, BNP, and cardiac biomarker testing
- Blood gas, electrolytes, and metabolite testing
- Platform competition — Abbott i-STAT, Radiometer, and Siemens
4. Infectious Disease POC
- Influenza, RSV, COVID, and combination panels
- Strep and urinary tract infection testing
- Syndromic POC panels — BioFire and competitors
5. Chronic Disease POC
- Glucose and HbA1c monitoring
- Continuous glucose monitoring integration with POC
- Lipid, INR, and metabolic testing
6. At-Home Testing
- OTC diagnostics and direct-to-consumer testing
- Prescription home test markets
- Regulatory framework for home-use IVD
7. POC Molecular Testing
- GeneXpert and ID NOW platform competition
- Near-patient NGS
- CLIA waiver strategy
8. Microfluidics and Biosensors
- Next-generation POC platform technologies
- Smartphone-connected diagnostics
- Key developers and competitive landscape
9. Competitive Landscape
- Abbott, Roche, Siemens Healthineers, QuidelOrtho, and emerging players
- New entrants and consumer diagnostics companies
- M&A and partnership activity 2023-2025
10. Regional Market Analysis
- 10.1 North America (U.S., Canada, Mexico)
- 10.2 Europe (38 countries)
- 10.3 Asia-Pacific (18 countries)
- 10.4 Latin America (22 countries)
- 10.5 Middle East (11 countries)
- 10.6 Africa and Rest of World
11. Strategic Conclusions and Recommendations
- Highest-priority opportunities by application and region
- Market entry and expansion strategies
- M&A, partnership and investment priorities
12. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Emergency and Critical Care POC — Platform Comparison and Leading Suppliers 2025
Table 2. Infectious Disease POC — Application Landscape and Leading Suppliers 2025
Table 3. Chronic Disease POC — Platform Comparison and Leading Suppliers 2025
Table 4. At-Home Testing — Market Segments and Regulatory Framework 2025
Table 5. POC Molecular Testing — Platform Comparison 2025
Table 6. Microfluidics and Biosensors — Technology Status and Key Developers 2025
Table 7. Leading Suppliers and Competitive Positioning — POC Testing 2025
Table 8. M&A and Partnership Activity in POC Testing 2023-2025
Table 9. Regulatory Pathway Summary by Application and Region 2025
Table 10. Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
